STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #912 by analyst upside · 2026-06-27
PRAX
Praxis Precision Medicines, Inc.
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+88.4%
implied upside to consensus target
Current Price $327.79
Consensus Target $617.67
Bull Target $1201.0
Bear Target $162.0
Analysts Covering 18
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
14
Hold
1
Sell
1
52-Week Low $37.19
52-Week High $366.52
YTD Return +14.5%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E -33.4x
EPS (TTM) $-13.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $37.19
52-Week High $366.52
Current Price $327.79
Bear Target $162.0
Bull Target $1201.0
● Now $327.79 ● Target $617.67
TRADING DATA
Avg Volume 460K
YTD Return +14.5%
Analyst Count 18
Consensus Buy
Upside to Target +88.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Praxis Precision Medicines, Inc. (PRAX) is currently trading at $327.79 with a Wall Street consensus price target of $617.67, implying potential upside of 88.4% over the next 12 months. 18 analysts currently cover PRAX, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1201.0, while the most cautious has a target of $162.0.

PRAX operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 14.5% year-to-date and is currently trading near the upper end of its 52-week range of $37.19 – $366.52.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital ● Initiated
Outperform 2026-06-18 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-06-02 14% win rate (7 calls)
Truist Securities — Reiterated
Buy → Buy 2026-06-02 Building track record
Deutsche Bank — Reiterated
Buy → Buy 2026-06-02 Building track record
Wedbush — Reiterated
Underperform → Underperform 2026-06-02 Building track record
Baird — Reiterated
Outperform → Outperform 2026-06-02 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-02 31% win rate (48 calls)
BTIG — Reiterated
Buy → Buy 2026-06-02 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →